louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT05788055: Helicobacter Pylori Infection in Acute Myocardial Infarction Patients
Official title: The Study of Helicobacter Pylori Infection in Acute Myocardial Infarction Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Acute Coronary Syndrome
Lead sponsor: Sohag University
Sponsor class: OTHER
First posted: 2023-03-28
Enrollment: 200
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All patients presenting by acute coronary syndrome to Coronary Care Units and the chronic stable angina patients.

Brief summary: This study aims to investigate the association between H.Pylori and ACS .

Detailed description: The study is based on show the relationship between H.Pylori infection and Acute Coronary Syndrome .

Active H.Pylori infection is common in ACS and may represent a modifiable risk factor for upper gastrointestinal bleeding.

Eligibility criteria: Inclusion Criteria:

* All patients presenting by acute coronary syndrome to Coronary Care Units, Internal Medicine Department, Sohag Faculty of Medicine from 18 .

Exclusion Criteria:

* 1.Patients with Cardiogenic Shock. 2. Renal Impairment.(Creatinine Clearence \<60) 3. A known systemic inflammatory condition. 4.They had taken any antibiotics in the previous 1 months. 5.They had taken any proton pump inhibitors in previous 2 weeks. 6.Gastrointestinal Bleeding.

Primary outcomes:
measure: Comparison of results of H.Pylori antigen with ACS
timeFrame: from the day of admission to the day of disharge of sohag university hospitals
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
citation: Lai CY, Yang TY, Lin CL, Kao CH. Helicobacter pylori infection and the risk of acute coronary syndrome: a nationwide retrospective cohort study. Eur J Clin Microbiol Infect Dis. 2015 Jan;34(1):69-74. doi: 10.1007/s10096-014-2207-7. Epub 2014 Jul 26.
Clinical trial NCT00887055: OPTIMA Bi-ventricular Capture Verification Study
Official title: Bi-ventricular Capture Verification Study
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Heart Failure
Lead sponsor: Guidant Corporation
Sponsor class: INDUSTRY
First posted: 2009-04-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE

Brief summary: The purpose of this study is to characterize the morphology (shape) of the intracardiac electrograms(EGM) from patients with a resynchronization therapy device.

Detailed description: morphology of EGM during loss of capture in either right ventricle (RV) or left ventricle (LV) at different AV delays and LV offsets and during exercise. These EGM signals will be used to design and develop improved automatic threshold and automatic capture algorithms for CRT defibrillators (CRT-D). As well, the data collected from the study will be used to to develop other automatic algorithms for CRT-D, such as pacing parameter optimization.

Eligibility criteria: Inclusion Criteria:

* Signed informed consent indicating a willingness to participate, have indications for and have been implanted with a Guidant Renewal 4 CRT-D device

Exclusion Criteria:

* Patients in atrial fibrillation that cannot be cardioverted for the study, sustained uncontrolled ventricular tachycardia (VT), sinus rhythm \< 40 bpm or \> 100 bpm, complete AV node block, AV node ablation, Severe aortic valve stenosis (valve area \< 1.0 cm squared), frequent ectopic beats that would preclude adequate testing, lead in the great cardiac vein, women who are pregnant or who plan to become pregnant.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Ste-Foy
country: Canada
facility: Hopital Laval
state: Quebec
Study officials:
affiliation: Hopital Laval, 2725 Chemin Ste-Foy, Ste-Foy, Quebec, Canada G1V 4G5 418-656-8711
name: Francois Philippon, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00057655: Behavioral Health Services for Women Receiving Public Assistance
Official title: Access to Behavioral Health Services for Women on TANF
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Mental Disorders
Keywords: Social Welfare
Mentally Ill Persons
Mental Health Services
Lead sponsor: University of Pennsylvania
Sponsor class: OTHER
Collaborators: name: National Institute of Mental Health (NIMH)
First posted: 2003-04-08
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Time perspective: RETROSPECTIVE

Brief summary: The purpose of this study is to determine whether access to behavioral health services has been affected by welfare reform.

Detailed description: This study examines patterns of behavioral health service use among a group of female household heads who receive Temporary Assistance to Needy Families (TANF) and have serious mental illness (SMI). The findings from this study will be used to determine the feasibility of conducting a full-scale longitudinal study of the impact of welfare reform outcomes on female household heads who have SMI and are currently or formerly recipients of welfare.

Eligibility criteria: Inclusion Criteria:

* Female head of household on TANF at any time during first quarter of 1997 and used at least one behavioral health service during that quarter
* DSM IV diagnosis of serious mental illness

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Philadelphia
country: United States
facility: University of Pennsylvania, School of Social Work
state: Pennsylvania
Study officials:
References:
Clinical trial NCT01693055: Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid
Official title: Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid,Phase 4.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Orbital Fat Prolapse
Keywords: orbital Computed Tomography
baggy eyelids
orbital fat prolapse
UltheraTM
high intensity focused ultrasound
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Ulthera, Inc
First posted: 2012-09-26
Enrollment: 7
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Study title

* Safety and Efficacy Evaluation of UltheraTM in Treatment of Baggy Eyelid Study design
* single arm and Investigator Initiative pilot study


Eligibility criteria: Inclusion Criteria:

* Age \>20 years, Age \< 50 years
* people who want to improve baggy eyelid
* Information consent obtained

Exclusion Criteria:

* previous lower eyelid surgical history
* scar on lower eyelid after trauma
* bleeding tendency
* aesthetic addiction, drug abuse, alcohol abuse

Primary outcomes:
measure: The distance from the inferior orbital rim to the skin
timeFrame: Change from Screening in distance at 12weeks after Ulthera treatment
Secondary outcomes:
measure: The distance from the most protrusive baggy eyelid to the orbital septum
timeFrame: Change from Screening in distance at 12weeks after UltheraTM treatment
measure: Subject Satisfaction for baggy lower eyelid
timeFrame: Change from Screening in satisfaction at 4 weeks and 12weeks
measure: Improvement of baggy lower eyelid
timeFrame: Change from Screening in baggy lower eyelid at 12weeks after UltheraTM treatment
Other outcomes:
Locations:
city: Seongnam-si,
country: Korea, Republic of
facility: Seoul National Univ. Bundang Hospital, Gumi-dong, Bundang-gu
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Chanyeong Heo, Ph.D
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05897255: Effects of SEMG Biofeedback With Core Muscle Strengthening Exercises and Kinesiotaping on Diastasis Recti in Post-partum Women
Official title: Effects of SEMG Biofeedback With Core Muscle Strengthening Exercises and Kinesiotaping on Diastasis Recti in Post-partum Women
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Diastasis Recti Abdominis
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2023-06-09
Enrollment: 24
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Parallel Group Randomized Control Trial
Primary purpose: TREATMENT

Brief summary: Diastasis Rectus Abdominis is quite common during and after pregnancy. Abdominal core strengthening exercises have been proven to be very effective in reducing Inter rectus distance, however, the role of Biofeedback EMG assisted exercises in Diastasis Rectus have been poorly understood.

Detailed description: This study is a Randomized Control Trial in which posr-partum females with diastasis recti will be recruited into a control and two experimental groups. In control group, patients will receive standard conservative treatment, whereas, in first experimental group, participants will receive core strengthening exercises with kinesiotaping; and in second experimental group, core strengthening exercises with kinesiotaping will be assisted by SEMG biofeedback. Patients will be evaluated pre and post-treatment for Inter rectus distance, abdominal strength and quality of life.

Eligibility criteria: Inclusion Criteria:

* Post-partum women aged 18-40 years
* Post-partum females from 6 to 24 months
* Diastasis rectus abdominus distance more than 2cm at any of 3 levels
* Primiparous or multiparous
* Spontaneous vaginal delivery and LSCS

Exclusion Criteria:

* Having skin sensitivity to taping
* Open abdominal wounds
* Abdominal skin diseases
* Abdominal hernia
* Other abdominal or back surgical history
* Any heart or respiratory conditions
* Neurological diseases

Primary outcomes:
measure: Inter Rectus Distance between rectus abdominis muscles.
timeFrame: 6 weeks
Secondary outcomes:
measure: Abdominal Strength and core stability will be assessed by Mc Gill torso muscular endurance test battery.
timeFrame: 6 weeks
measure: Quality of life will be measured by SF-36
timeFrame: 6 weeks
Other outcomes:
Locations:
city: Islamabad
country: Pakistan
facility: Foundation University Islamabad
state: Federal
Study officials:
affiliation: Foundation University Islamabad
name: Ujala Afzal
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04289155: Individual Patient Compassionate Use of GX-I7
Official title: Individual Patient Compassionate Use of GX-I7
Study type: EXPANDED_ACCESS
Overall status: NO_LONGER_AVAILABLE
Conditions: Glioblastoma
High Grade Glioma
Recurrent Glioblastoma
Melanoma
Advanced Cancer
Lead sponsor: Genexine, Inc.
Sponsor class: INDUSTRY
First posted: 2020-02-28
Standard ages: CHILD
ADULT
OLDER_ADULT

Brief summary: Compassionate use of GX-I7 for patients with serious life-threatening illness that have exhausted all available therapies, with no other therapy options.

Detailed description: This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee and Single Patient IND approval.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

-

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Kangnam St. Mary's Hospital
Study officials:
References:
Clinical trial NCT06573255: Assessment of Cardiopulmonary Fitness in Healthy Adults
Official title: Assessment of Cardiopulmonary Fitness in Healthy Adults
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Healthy
Keywords: cardiorespiratory fitness
Lead sponsor: Hacettepe University
Sponsor class: OTHER
First posted: 2024-08-27
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study will include healthy adult subjects without any known internal disease.

Brief summary: This project was aimed to investigate cardiorespiratory fitness and the factors affecting cardiorespiratory fitness in healthy adults. The data obtained with this project will be normative values for the data obtained with CPET in healthy people.

Detailed description: Cardiorespiratory fitness is one of the 'health-related physical fitness' components of physical fitness and can be expressed as 'the ability of the heart, lung and vascular system to deliver oxygen and nutrients to working muscles'. Cardiopulmonary exercise testing (CPET) is a common procedure used to assess cardiopulmonary fitness, identify physiological factors limiting exercise, identify potential therapeutic targets for these factors, and evaluate the effects of an intervention. Therefore, in this project, it was aimed to investigate cardiorespiratory fitness and the factors affecting cardiorespiratory fitness in healthy adults. The data obtained with this project will be normative values for the data obtained with CPET in healthy people.

Eligibility criteria: Inclusion Criteria:

* 18-65 years of age,
* Volunteering to participate in the study,
* Co-operation,
* Being able to ambulate.

Exclusion Criteria:

* Having any known respiratory, cardiac, neurological or other internal disease or malignant disease,
* Having any problem or musculoskeletal system disorder that prevents walking,
* To have undergone any surgery within the last six months

Primary outcomes:
measure: Cardiorespiratory Fitness
timeFrame: This test takes 15 to 20 minutes.
Secondary outcomes:
measure: Respiratory Function Test
timeFrame: This test takes 3 to 5 minutes.
measure: Respiratory Muscle Strength Test
timeFrame: This test takes 3 to 5 minutes.
measure: Physical Activity
timeFrame: This questionnaire takes 1 minute.
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Hacettepe University
Study officials:
affiliation: Hacettepe Univesity
name: Ebru Calik Kutukcu, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01878955: The Use Of AMH for the Discrimination of Polycystic and Multicystic Ovaries in Nonhyperandrogenic Patients
Official title: Elevation of AMH Resulted From Ovarian Structural Properties or Effects of Gonadotropines
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Polycystic Ovary Syndrome
Keywords: Antimullarian hormone(AMH)
Polycystic Ovary
Multicystic Ovary
Lead sponsor: Izmir Katip Celebi University
Sponsor class: OTHER
First posted: 2013-06-17
Enrollment: 140
Sex: FEMALE
Minimum age (years): 15
Maximum age (years): 43
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: primary care clinic

Brief summary: AMH is a member of the transforming growth factor family. It is produced by the granulosa cells from 36th weeks of pregnancy.Ovarian granulosa cells are the only source of the antimüllerian hormone. AMH production continues until response to exogenous FSH occurs and follicles reach 4-6 mm in diameter.The number of follicles in patients with polycystic ovaries are 2-6 times higher than normal women. Serum AMH levels are 2-3 times higher in patients with PCOS. The cause of elevated serum AMH levels in patients with PCOS is unknown. There are data showing elevated serum AMH level is due to the increase in the number of follicles 2-8 mm in diameter. Although there is no precise definition; multicystic ovarian is defined by the presence of more than six follicles 4-9 mm in diameter and mixed morphologically with PCO. PCO and multicystic ovaries are distinguished by the absence of the increase in stroma / volume.The aim of this study is to investigate whether there is a difference of serum AMH levels between patients with PCO or multicystic ovaries. A primary goal is to investigate the usability of AMH as a marker besides ultrasound for discrimination of nonhyperandrogenic patients with PCO or multicystic ovaries.

Detailed description: It is planned to compare the values of FSH/LH, AMH, and 75 gr OGTT between 20 patients diagnosed as PCOS according to the AES-Rotterdam criteria and 20 patients with multicystic ovarian structure but do not provide the PCOS-D3 criteria. The second purpose of this study is to investigate the mechanism that leads to the elevation of AMH in patients with PCOS, and to reveal the effects of intraovarian paracrine factors,insulin resistance and FSH /LH.

Eligibility criteria: Inclusion Criteria:

* Between the ages of 15-43
* \>6 4-9 mm follicles in bilateral ovaries at ultrasonographic examination
* Increased ovarian volume (\>10 ml )

Exclusion Criteria:

* Hormonal drug users
* Late onset congenital adrenal hyperplasia,androgen secreted ovarian or adrenal tumors

Primary outcomes:
measure: Anti-Müllerian Hormone level 0.5ng/ml -14ng/ml.
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Izmir Katip Çelebi University
name: Serpil Aydoğmuş, assoc prof
role: STUDY_DIRECTOR
References:
Clinical trial NCT02120755: A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
Official title: A Randomized Comparison of AmnioClear™ Human Allograft Amniotic Membrane vs. Moist Wound Dressing in the Treatment of Diabetic Wounds
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE4
Conditions: Diabetic Foot Ulcers
Wound Care
Lead sponsor: Liventa Bioscience
Sponsor class: INDUSTRY
First posted: 2014-04-23
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This research project is testing a product called AmnioClear™ which is an amniotic membrane graft processed for Liventa Bioscience formerly AFCell Medical. AmnioClear™ allograft human amniotic membrane is regulated solely under section 361 of the Public Health Service Act.

The purpose of the study is to see if this treatment works to accelerate the healing time of chronic wounds.


Eligibility criteria: Inclusion Criteria:

* Stable Type I or II diabetes mellitus
* At least one chronic diabetic ulcer
* Full-thickness ulcer size from 1-8 cm2.

Exclusion Criteria:

* Concurrent use of corticosteroids, NSAIDs immuno-suppressive or cytotoxic agents
* Bleeding disorders
* Ulcer with muscle, tendon, capsule or bone involvement

Primary outcomes:
measure: Reduction in Wound Size
timeFrame: 12 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Durham
country: United States
facility: Duke University
state: North Carolina
Study officials:
References:
Clinical trial NCT00426855: Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)
Official title: Weekly Bendamustine and Bortezomib Combination Therapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or B-CLL: A Single-Center Phase 2 Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Lymphoma, Non-Hodgkin
Keywords: Lymphoma, Non-Hodgkin, Low-Grade
Lead sponsor: Kantonsspital Aarau
Sponsor class: OTHER
Collaborators: name: Kantonsspital Aarau
First posted: 2007-01-25
Enrollment: 12
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether the combination of bendamustine and bortezomib in patients with indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia is safe and tolerable.

Detailed description: Bendamustin and bortezomib have been shown to be effective in the treatment of patients with indolent Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL). Both compounds appear not to be cross-resistant with prior therapy. Therefore, it is of interest to combine bendamustine and bortezomib in this patient population.

Preliminary results from patients with multiple myeloma showed that the combination of bendamustine and bortezomib is efficacious and well tolerated. However, there are so far no data on this combination in patients with NHL or CLL.

Eligibility criteria: Inclusion Criteria:

* Symptomatic recurrent or refractory indolent NHL or B-CLL
* Adequate organ and bone marrow function
* Karnofsky greater than 50%

Exclusion Criteria:

* Candidates for autologous stem cell transplantation
* Secondary high grade lymphoma
* Concurrent severe medical condition

Primary outcomes:
measure: Optimal Bendamustine Dosage for Further Studies
timeFrame: Three weeks after treatment termination
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Cantonal Hospital of Aarau, Switzerland
name: Peter R Moosmann, MD PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Moosmann P, Heizmann M, Kotrubczik N, Wernli M, Bargetzi M. Weekly treatment with a combination of bortezomib and bendamustine in relapsed or refractory indolent non-Hodgkin lymphoma. Leuk Lymphoma. 2010 Jan;51(1):149-52. doi: 10.3109/10428190903275602. No abstract available.
Clinical trial NCT02583555: Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users
Official title: Randomised Case Management Study to Reduce Health Care Utilization for Frequent Hospital Care Users
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Quality of Life
Keywords: Quality of Life
Health Care Utilization
Lead sponsor: Region Sjælland
Sponsor class: OTHER
Collaborators: name: Health Navigator
First posted: 2015-10-22
Enrollment: 400
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: The purpose of this study is to identify persons with high risk of frequent hospital admissions and by counselling by one in depth interview followed by frequent telephone contacts improve their quality of life and reduce their healthcare utilization.

Detailed description: Participants are identified by administrative data and a model predicting high risk of future healthcare utilization. Participants are invited to the study by mail. After informed consent participants are randomized to either active treatment or control 3:1. Active patients have an in depth interview with a specially trained nurse. Further counselling by telephone weekly for 6-9 months.

Quality of Life is measured by SF-36 every 3 months for one year both in active participants and in controls.

Eligibility criteria: Inclusion Criteria:

* Patient \> 18 years
* Recent history of contact with hospital
* Anticipated sustained high visit frequency

Exclusion Criteria:

* Dementia (ICD10: F00-F03 or F051)
* Psychoses (ICD10: F20-F29)
* Drug abuse (ICD10: F10-F19)
* Metastases (ICD10: C77-C80)
* Hearing impairment or language difficulties
* Life expectancy \< 1 year No telephone

Primary outcomes:
measure: Quality of Life reported by the participants with use of Short Form 36
timeFrame: Questionaire Short Form-36 Every 3 months for one year
measure: Health Care Utilization - Admissions to and days in hospital
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Roskilde
country: Denmark
facility: Regional Research
Study officials:
affiliation: Research Consultant
name: Knud Rasmussen, MD DMSci
role: PRINCIPAL_INVESTIGATOR
References: